Emerging agents and regimens for AML

Table 2 Summary of venetoclax-based combinations in AML

Combination	Phase	Disease status	Patient number	CR/CRi rate, %	References
FLA-Ida	Retrospective	R/R AML	13	69%	[9]
FLAG-ida	Ib/II	ND AML R/R AML	27 35	89% in ND AML 66% in R/R AML	[10, 11]
CAVEAT (5 + 2)	Ib	ND AML	51	72% in all 97% in de novo AML 43% secondary AML	[12]
DEC10	II	ND AML R/R AML	70 55	86% in ND AML 42% in R/R AML	[13]
CLIA	II	ND AML	18	88%	[14]
CLAD/LDAC, alternating with AZA	II	ND AML	48	94%	[15]
CPX-351	II	R/R AML ND AML	17 1	37%	[16]
CPX-351 LIT	Ib	ND AML	44 planned	NA	[17]
GO	Ib	R/R AML	24 planned	NA	[18]

ISSN: 1756-8722